We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Donnelley (DFIN) This Earnings Season?
Read MoreHide Full Article
Donnelley Financial Solutions (DFIN - Free Report) is set to announce second-quarter 2020 results on Aug 5.
The Zacks Consensus Estimate for quarterly revenues is pegged at $225 million, calling for a decline of 13.1%, year on year. The consensus mark for earnings is pegged at 42 cents per share, suggesting a 43.2% year-over-year plunge.
The company had reported mixed results for the first quarter. Donnelley Financial’s first-quarter earnings topped the Zacks Consensus Estimate but revenues fell short of the same.
Notably, the company’s earnings surpassed estimates in three of the preceding four quarters and missed in the other, the average surprise being 27.2%.
Donnelley Financial Solutions Inc. Price and Consensus
Donnelley Financial’s quarterly performance might have been hurt by sluggish compliance filing transactional activities due to COVID-19-related shutdowns and business disruptions.
Global IPO and M&A activities were slow during the second quarter, which is likely to have adversely impacted the company’s top-line performance. Notably, IPO and M&A account for roughly 40% and 30%, respectively, of the company’s total transactional business.
Nonetheless, Donnelley Financial’s aggressive approach toward managing its cost structure is anticipated to have provided some cushion to the company during the period in discussion.
What Our Model Says
Our proven model does not predict an earnings beat for Donnelley Financial this season. The combination of a positive Earnings ESP, and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), increases the chances of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell, before they’re reported, with our Earnings ESP Filter.
Donnelley Financial currently carries a Zacks Rank of 3 and has an Earnings ESP of 0.00%.
Stocks With Favorable Combinations
Here are some companies, which, per our model, have the right combination of elements to post an earnings beat this quarter:
Synaptics (SYNA - Free Report) has an Earnings ESP of +10.6 % and currently carries a Zacks Rank of 2.
Benefitfocus has an Earnings ESP of +6.25% and carries a Zacks Rank of 2, currently.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
What's in Store for Donnelley (DFIN) This Earnings Season?
Donnelley Financial Solutions (DFIN - Free Report) is set to announce second-quarter 2020 results on Aug 5.
The Zacks Consensus Estimate for quarterly revenues is pegged at $225 million, calling for a decline of 13.1%, year on year. The consensus mark for earnings is pegged at 42 cents per share, suggesting a 43.2% year-over-year plunge.
The company had reported mixed results for the first quarter. Donnelley Financial’s first-quarter earnings topped the Zacks Consensus Estimate but revenues fell short of the same.
Notably, the company’s earnings surpassed estimates in three of the preceding four quarters and missed in the other, the average surprise being 27.2%.
Donnelley Financial Solutions Inc. Price and Consensus
Donnelley Financial Solutions Inc. price-consensus-chart | Donnelley Financial Solutions Inc. Quote
Key Factors
Donnelley Financial’s quarterly performance might have been hurt by sluggish compliance filing transactional activities due to COVID-19-related shutdowns and business disruptions.
Global IPO and M&A activities were slow during the second quarter, which is likely to have adversely impacted the company’s top-line performance. Notably, IPO and M&A account for roughly 40% and 30%, respectively, of the company’s total transactional business.
Nonetheless, Donnelley Financial’s aggressive approach toward managing its cost structure is anticipated to have provided some cushion to the company during the period in discussion.
What Our Model Says
Our proven model does not predict an earnings beat for Donnelley Financial this season. The combination of a positive Earnings ESP, and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), increases the chances of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell, before they’re reported, with our Earnings ESP Filter.
Donnelley Financial currently carries a Zacks Rank of 3 and has an Earnings ESP of 0.00%.
Stocks With Favorable Combinations
Here are some companies, which, per our model, have the right combination of elements to post an earnings beat this quarter:
Cogent Communications Holdings (CCOI - Free Report) has an Earnings ESP of +11.66% and carries a Zacks Rank of 2, at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Synaptics (SYNA - Free Report) has an Earnings ESP of +10.6 % and currently carries a Zacks Rank of 2.
Benefitfocus has an Earnings ESP of +6.25% and carries a Zacks Rank of 2, currently.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>